Drs. Jordan Alana Ciuro, Margo Gerke, and Mehmet A. Bilen, of Winship Cancer Institute at Emory University, discuss their research on the real-world outcomes of Lu-PSMA-617 in mCRPC in a racially diverse patient population. The conversation also explores what initiatives providers should implement to overcome health care disparities and improve representation of diverse patient populations in clinical trials, as well as what they believe are the biggest gaps in current research regarding Lu-PSMA. The results were presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Real-World Outcomes of Lu-PSMA-617 in mCRPC
By Jordan Ciuro, MD, Margo Gerke, Mehmet A. Bilen, MD - Last Updated: February 14, 2025Related Posts
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
The combination demonstrated a manageable safety profile with evidence of EZH2 pharmacodynamic inhibition and OR.
Final TALAPRO-2 results show talazoparib + enzalutamide significantly improves survival in patients with HRR-deficient mCRPC.
Tala/enza demonstrated improvement in OS compared with enza alone as 1L treatment in patients with mCRPC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.